Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis

References

• WHO Coronavirus Disease (COVID-19) Dashboard 2021.
   Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–11. doi:10.1038/s41586-020-2798-3.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu C-Y, Desai A, de Lima Lopes G, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18. doi:10.1016/S0140-6736(20)31187-9.
   PubMed Web of Science ®Google Scholar
• Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian veneto region: adverse outcomes in patients with cancer. Nat Cancer. 2020;1(8):784–8. doi:10.1038/s43018-020-0104-9.
   PubMedGoogle Scholar
• Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218–23. doi:10.1038/s41591-020-0979-0.
   PubMed Web of Science ®Google Scholar
• Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, Curigliano G, de Azambuja E. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. doi:10.1016/j.ejca.2020.08.011.
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. doi:10.1016/S1470-2045(20)30096-6.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor Educate Ann Oncol. 2021;32(5):579–81. doi:10.1016/j.annonc.2021.01.068.
   PubMed Web of Science ®Google Scholar
• van der Veldt AAM, Oosting SF, Dingemans AMC, Fehrmann RSN, GeurtsvanKessel C, Jalving M, Rimmelzwaan GF, Kvistborg P, Blank CU, Smit EF. et al. COVID-19 vaccination: the VOICE for patients with cancer. Nat Med. 2021;27(4):568–9. doi:10.1038/s41591-021-01240-w.
   PubMed Web of Science ®Google Scholar
• Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–39. doi:10.1038/s41418-020-00720-9.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, Kaklamani V, Dietrich P-Y, Taylor BS, Simand P-F. et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091.e2–8.e2. doi:10.1016/j.ccell.2021.06.009.
   Web of Science ®Google Scholar
• Agbarya A, Sarel I, Ziv-Baran T, Agranat S, Schwartz O, Shai A, Nordheimer S, Fenig S, Shechtman Y, Kozlener E. et al. Efficacy of the mRNA-Based BNT162b2 COVID-19 vaccine in patients with solid malignancies treated with anti-neoplastic drugs. Cancers Basel. 2021;13(16):4191. doi:10.3390/cancers13164191.
   PubMed Web of Science ®Google Scholar
• Amatu A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, Cassingena A, Tosi F, Ghezzi S, Campisi D. et al. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. Eur J Cancer. 2022;163:16–25. doi:10.1016/j.ejca.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, Hatami F, Fereidouni M, Welsh JS, Javadinia SA. Immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2022;40(1):26–34. doi:10.1080/07357907.2021.1992420.
   PubMed Web of Science ®Google Scholar
• Baek YJ, Lee Y-J, Park SR, Kim KH, Beom S-H, Lee C-K, Shin SJ, Rha SY, Kim S, Lee KH. et al. Immunogenicity and safety of vaccines against coronavirus disease in actively treated patients with solid tumors: a prospective cohort study. Cancer Res Treat. 2023;55(3):746–57. doi:10.4143/crt.2022.1541.
   PubMed Web of Science ®Google Scholar
• Balcells ME, Le Corre N, Durán J, Ceballos ME, Vizcaya C, Mondaca S, Dib M, Rabagliati R, Sarmiento M, Burgos PI. et al. Reduced immune response to inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a cohort of immunocompromised patients in chile. Clin Infect Dis. 2022;75(1):594–602. doi:10.1093/cid/ciac167.
   Google Scholar
• Barrière J, Chamorey E, Adjtoutah Z, Castelnau O, Mahamat A, Marco S, Petit E, Leysalle A, Raimondi V, Carles M. et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053–5. doi:10.1016/j.annonc.2021.04.019.
   PubMed Web of Science ®Google Scholar
• Cavanna L, Citterio C, Biasini C, Madaro S, Bacchetta N, Lis A, Cremona G, Muroni M, Bernuzzi P, Lo Cascio G. et al. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: seropositivity and safety. A prospective observational study in Italy. Eur J Cancer. 2021;157:441–9. doi:10.1016/j.ejca.2021.08.035.
   PubMed Web of Science ®Google Scholar
• Cavic G, Almonte AA, Hicks SM, Neeman T, Wang J-W, Brew S, Choi PY, Cockburn I, Gardiner EE, Yip D. et al. Response to COVID-19 vaccination in patients on cancer therapy: analysis in a SARS-CoV-2-naïve population. Asia Pac J Clin Oncol. 2024; doi:10.1111/ajco.14047.
   PubMed Web of Science ®Google Scholar
• Cernera G, Gelzo M, De Placido P, Ottaviano M, Pietroluongo E, Raia M, Scalia G, Tortora M, Castaldo G, Formisano P. et al. Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response. Front Immunol. 2023;14:1233056. doi:10.3389/fimmu.2023.1233056.
   PubMedGoogle Scholar
• Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y. et al. Humoral responses after SARS-CoV-2 mRNA vaccination and breakthrough infection in cancer patients. Mayo Clin Proc Innov Qual Outcomes. 2022;6(2):120–5. doi:10.1016/j.mayocpiqo.2021.12.004.
   PubMedGoogle Scholar
• Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C. et al. Humoral and T-Cell immune response after 3 doses of messenger RNA severe acute respiratory syndrome coronavirus 2 vaccines in fragile patients: The Italian VAX4FRAIL Study. Clin Infect Dis. 2023;76(3):426–38. doi:10.1093/cid/ciac404.
   Google Scholar
• Cortés A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, Martin A, Chamorro J, Rosero D, Fernández M. et al. Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. Eur J Cancer. 2022;166:229–39. doi:10.1016/j.ejca.2022.02.017.
   PubMed Web of Science ®Google Scholar
• Dalu D, Tarkowski M, Ruggieri L, Cona MS, Gabrieli A, De Francesco D, Fasola C, Ferrario S, Gambaro A, Masedu E. et al. Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients. Int J Cancer. 2023; doi:10.1002/ijc.34817.
   Google Scholar
• Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini MT, Gariazzo L, Pontone M, Monti A, Campo F, Taraborelli E. et al. Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Cancer Res. 2021;27(24):6815–23. doi:10.1158/1078-0432.CCR-21-2439.
   PubMed Web of Science ®Google Scholar
• Di Noia V, Pimpinelli F, Renna D, Maccallini MT, Gariazzo L, Riva F, Sperandio E, Giannarelli D, Cognetti F. Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer. Ann Oncol. 2022;33(5):563–5. doi:10.1016/j.annonc.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Østerlev S, Kragh A, Frederiksen H, Ditzel HJ. Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination. Cancer Cell. 2022;40(4):338–9. doi:10.1016/j.ccell.2022.02.011.
   PubMed Web of Science ®Google Scholar
• Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Østerlev S, Vestergaard H, Justesen US, Johansen IS, Frederiksen H, Ditzel HJ. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034–6. doi:10.1016/j.ccell.2021.07.016.
   PubMed Web of Science ®Google Scholar
• Eliakim-Raz N, Massarweh A, Stemmer A, Stemmer SM. Durability of Response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment. JAMA Oncol. 2021;7(11):1716–18. doi:10.1001/jamaoncol.2021.4390.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, Tippu Z, Farag S, Rogiers A, Harvey R. et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022;40(2):114–16. doi:10.1016/j.ccell.2021.12.013.
   PubMed Web of Science ®Google Scholar
• Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre JD, Gallien S, Zalcman G, Pawlotsky JM, Tournigand C. SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 2022;8(4):612–7. doi:10.1001/jamaoncol.2021.7777.
   PubMed Web of Science ®Google Scholar
• Figueiredo JC, Merin NM, Hamid O, Choi SY, Lemos T, Cozen W, Nguyen N, Finster LJ, Foley J, Darrah J. et al. Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with cancer. Cancer Res. 2021;81(24):6273–80. doi:10.1158/0008-5472.CAN-21-3554.
   PubMed Web of Science ®Google Scholar
• Fong D, Mair MJ, Mitterer M. High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine. Eur J Cancer. 2021;154:4–6. doi:10.1016/j.ejca.2021.05.036.
   PubMed Web of Science ®Google Scholar
• Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T. et al. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. J Infect Chemother. 2022;28(4):516–20. doi:10.1016/j.jiac.2021.12.021.
   PubMed Web of Science ®Google Scholar
• Giuliano A, Kuter B, Pilon‐Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs‐Soriano K. et al. Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients. Cancer Commun (Lond). 2023;43(7):749–64. doi:10.1002/cac2.12453.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J. et al. Evaluation of antibody response to SARS-CoV-2 mRNA-1273 vaccination in patients with cancer in florida. JAMA Oncol. 2022;8(5):748–54. doi:10.1001/jamaoncol.2022.0001.
   PubMed Web of Science ®Google Scholar
• Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A. et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507–13. doi:10.1001/jamaoncol.2021.2675.
   PubMed Web of Science ®Google Scholar
• Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A. et al. Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17(2):239–51. doi:10.1016/j.jtho.2021.10.015.
   PubMed Web of Science ®Google Scholar
• Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283. doi:10.1016/j.esmoop.2021.100283.
   PubMed Web of Science ®Google Scholar
• Guven DC, Incesu FGG, Yildirim HC, Erul E, Chalabiyev E, Aktas BY, Yuce D, Arik Z, Kilickap S, Aksoy S. et al. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy. Int J Cancer. 2023;152(4):679–85. doi:10.1002/ijc.34280.
   PubMed Web of Science ®Google Scholar
• Haidar G, Agha M, Bilderback A, Lukanski A, Linstrum K, Troyan R, Rothenberger S, McMahon DK, Crandall MD, Sobolewksi MD. et al. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clin Infect Dis. Clin Infect Dis. 2022;75(1):630–44. doi:10.1093/cid/ciac103.
   PubMed Web of Science ®Google Scholar
• Heudel P, Favier B, Assaad S, Zrounba P, Blay J-Y. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients. Ann Oncol. 2021;32(11):1443–4. doi:10.1016/j.annonc.2021.07.012.
   PubMed Web of Science ®Google Scholar
• Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, Basal FB, Bilgetekin I, Sutcuoglu O, Yazici O. et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncol. 2021;17(33):4447–56. doi:10.2217/fon-2021-0597.
   PubMed Web of Science ®Google Scholar
• Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Serra F, Comolli G, Sarasini A, Sammartino JC, Ferrari A. et al. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern. ESMO Open. 2022;7(5):100574. doi:10.1016/j.esmoop.2022.100574.
   PubMed Web of Science ®Google Scholar
• Lau DK, Aresu M, Planche T, Tran A, Lazaro-Alcausi R, Duncan J, Kidd S, Cromarty S, Begum R, Rana I. et al. SARS-CoV-2 vaccine immunogenicity in patients with gastrointestinal cancer receiving systemic anti-cancer therapy. Oncologist. 2023;28(1):1–8. doi:10.1093/oncolo/oyac230.
   PubMed Web of Science ®Google Scholar
• Ligumsky H, Dor H, Etan T, Golomb I, Nikolaevski-Berlin A, Greenberg I, Halperin T, Angel Y, Henig O, Spitzer A. et al. Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer. Lancet Oncol. 2022;23(2):193–5. doi:10.1016/S1470-2045(21)00715-4.
   PubMed Web of Science ®Google Scholar
• Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, Nikolaevski-Berlin A, Greenberg I, Halperin T, Wasserman A. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. J Natl Cancer Inst. 2022;114(2):203–9. doi:10.1093/jnci/djab174.
   PubMedGoogle Scholar
• Lim SH, Choi SH, Ji YS, Kim SH, Kim CK, Yun J, Park SK. Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia Pac J Clin Oncol. 2023; doi:10.1111/ajco.13959.
   Web of Science ®Google Scholar
• Linardou H, Spanakis N, Koliou G-A, Christopoulou A, Karageorgopoulou S, Alevra N, Vagionas A, Tsoukalas N, Sgourou S, Fountzilas E. et al. Responses to SARS-CoV-2 vaccination in patients with cancer (recover study): a prospective cohort study of the hellenic cooperative oncology group. Cancers Basel. 2021;13(18):4621. doi:10.3390/cancers13184621.
   PubMed Web of Science ®Google Scholar
• Liontos M, Terpos E, Markellos C, Zagouri F, Briasoulis A, Katsiana I, Skafida E, Fiste O, Kunadis E, Andrikopoulou A. et al. Immunological response to COVID-19 vaccination in ovarian cancer patients receiving PARP Inhibitors. Vaccines. 2021;9(10):1148. doi:10.3390/vaccines9101148.
   Web of Science ®Google Scholar
• Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K, Pammer M, Rauscher I, Salzer HJF, Doppler S. et al. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell. 2021;39(9):1171–2. doi:10.1016/j.ccell.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Margalit O, Shacham-Shmueli E, Itay A, Berger R, Halperin S, Jurkowicz M, Levin EG, Olmer L, Regev-Yochay G, Lustig Y. et al. Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours. Eur J Cancer. 2022;168:51–5. doi:10.1016/j.ejca.2022.03.013.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, Benouaich-Amiel A, Ben-Zvi H, Moskovits N, Brenner B. et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133–40. doi:10.1001/jamaoncol.2021.2155.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Tschernichovsky R, Stemmer A, Benouaich-Amiel A, Siegal T, Eliakim-Raz N, Stemmer SM, Yust-Katz S. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. J Neurooncol. 2022;156(3):483–9. doi:10.1007/s11060-021-03911-7.
   PubMed Web of Science ®Google Scholar
• Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–78. doi:10.1016/S1470-2045(21)00213-8.
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS. et al. Immunogenicity and Reactogenicity of SARS-CoV-2 vaccines in patients with cancer: The CANVAX cohort study. J Clin Oncol. 2022;40(1):12–23. doi:10.1200/JCO.21.01891.
   PubMed Web of Science ®Google Scholar
• Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A. et al. Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study. Ann Oncol. 2022;33(7):740–2. doi:10.1016/j.annonc.2022.04.002.
   PubMed Web of Science ®Google Scholar
• Oosting SF, van der Veldt AAM, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AMC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M. et al. Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. Lancet Oncol. 2022;23(7):833–5. doi:10.1016/S1470-2045(22)00203-0.
   PubMed Web of Science ®Google Scholar
• Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AMC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M. et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22(12):1681–91. doi:10.1016/S1470-2045(21)00574-X.
   PubMed Web of Science ®Google Scholar
• Palich R, Veyri M, Marot S, Vozy A, Gligorov J, Maingon P, Marcelin A-G, Spano J-P. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Ann Oncol. 2021;32(8):1051–3. doi:10.1016/j.annonc.2021.04.020.
   PubMed Web of Science ®Google Scholar
• Provencio M, Rodríguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, López Vivanco G, Guirado M, Benítez G. et al. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022;11(1):53–63. doi:10.21037/tlcr-21-504.
   PubMed Web of Science ®Google Scholar
• Rahav G, Lustig Y, Lavee J, Benjamini O, Magen H, Hod T, Shem-Tov N, Shmueli ES, Merkel D, Ben-Ari Z. et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. EClinicalMedicine. 2021;41:101158. doi:10.1016/j.eclinm.2021.101158.
   PubMedGoogle Scholar
• Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S. et al. Neutralizing antibodies to omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. Front Immunol. 2023;14:1104124. doi:10.3389/fimmu.2023.1104124.
   PubMed Web of Science ®Google Scholar
• Scoccianti S, Delli Paoli C, Infantino M, Paoletti L, Caini S, Meacci F, Russo S, Esposito M, Fondelli S, Grilli Leonulli B. et al. Immunogenicity after two and three doses of mRNA vaccine in patients with cancer treated with exclusive radiotherapy. Int Immunopharmacol. 2023;122:110460. doi:10.1016/j.intimp.2023.110460.
   PubMed Web of Science ®Google Scholar
• Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M. et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40(1):3–5. doi:10.1016/j.ccell.2021.11.006.
   PubMed Web of Science ®Google Scholar
• Shmueli ES, Itay A, Margalit O, Berger R, Halperin S, Jurkowicz M, Levin EG, Levy I, Olmer L, Regev-Yochay G. et al. Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study. Eur J Cancer. 2021;157:124–31. doi:10.1016/j.ejca.2021.08.007.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, Peyton KL, Uhrlaub JL, Ripperger TJ, Jergović M. et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27(11):2002–11. doi:10.1038/s41591-021-01542-z.
   PubMed Web of Science ®Google Scholar
• Su E, Fischer S, Demmer-Steingruber R, Nigg S, Güsewell S, Albrich WC, Rothermundt C, Silzle T, Kahlert CR. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment. ESMO Open. 2022;7(5):100587. doi:10.1016/j.esmoop.2022.100587.
   PubMed Web of Science ®Google Scholar
• Terpos E, Zagouri F, Liontos M, Sklirou AD, Koutsoukos K, Markellos C, Briasoulis A, Papanagnou E-D, Trougakos IP, Dimopoulos M-A. et al. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. J Hematol Oncol. 2021;14(1):86. doi:10.1186/s13045-021-01099-x.
   PubMed Web of Science ®Google Scholar
• Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA. et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081.e2–90.e2. doi:10.1016/j.ccell.2021.06.002.
   Web of Science ®Google Scholar
• Trontzas IP, Vathiotis I, Economidou C, Petridou I, Gomatou G, Grammoustianou M, Tsamis I, Syrigos N, Anagnostakis M, Fyta E. et al. Assessment of Seroconversion after SARS-CoV-2 vaccination in patients with lung cancer. Vaccines. 2022;10(4):618. doi:10.3390/vaccines10040618.
   Web of Science ®Google Scholar
• Valanparambil RM, Carlisle J, Linderman SL, Akthar A, Millett RL, Lai L, Chang A, McCook-Veal AA, Switchenko J, Nasti TH. et al. Antibody response to COVID-19 mRNA vaccine in patients with lung cancer after primary immunization and booster: reactivity to the SARS-CoV-2 WT virus and omicron variant. J Clin Oncol. 2022;40(33):3808–16. doi:10.1200/JCO.21.02986.
   PubMed Web of Science ®Google Scholar
• Wagner A, Garner-Spitzer E, Schötta A-M, Orola M, Wessely A, Zwazl I, Ohradanova-Repic A, Weseslindtner L, Tajti G, Gebetsberger L. et al. SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients – a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease. Front Immunol. 2022;13:889138. doi:10.3389/fimmu.2022.889138.
   PubMed Web of Science ®Google Scholar
• Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç, Öztürk A, Perkin P, Demirtaş D, Erdemoglu E. et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022;18(10):1235–44. doi:10.2217/fon-2021-1248.
   PubMed Web of Science ®Google Scholar
• Zagouri F, Papatheodoridi A, Liontos M, Briasoulis A, Sklirou AD, Skafida E, Fiste O, Markellos C, Andrikopoulou A, Koutsoukos K. et al. Assessment of postvaccination neutralizing antibodies response against SARS-CoV-2 in cancer patients under treatment with targeted agents. Vaccines. 2022;10(9):1474. doi:10.3390/vaccines10091474.
   Web of Science ®Google Scholar
• Zagouri F, Terpos E, Fiste O, Liontos M, Briasoulis A, Katsiana I, Skafida E, Markellos C, Kunadis E, Andrikopoulou A. et al. SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. Breast. 2021;60:58–61. doi:10.1016/j.breast.2021.08.017.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–55. doi:10.1016/S0895-4356(01)00377-8.
   PubMed Web of Science ®Google Scholar
• Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005;58(9):894–901. doi:10.1016/j.jclinepi.2005.01.006.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(jul22 1):d4002. doi:10.1136/bmj.d4002.
   PubMed Web of Science ®Google Scholar
• Brodziak A, Sigorski D, Osmola M, Wilk M, Gawlik-Urban A, Kiszka J, Machulska-Ciuraj K, Sobczuk P. Attitudes of patients with cancer towards vaccinations-results of online survey with special focus on the vaccination against COVID-19. Vaccines (Basel). 2021 Apr 21;9(5):411. doi:10.3390/vaccines9050411.
   PubMed Web of Science ®Google Scholar
• Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, Punie K, Westphalen CB, Morgan G, Pronzato P. et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103365. doi:10.1016/j.critrevonc.2021.103365.
   PubMed Web of Science ®Google Scholar
• Peng X, Gao P, Wang Q, Wu H-G, Yan Y-L, Xia Y, Wang J-Y, Lu F, Pan H, Yang Y. et al. Prevalence and Impact Factors of COVID-19 vaccination hesitancy among breast cancer survivors: A multicenter cross-sectional study in China. Front Med. 2021;8:741204. doi:10.3389/fmed.2021.741204.
   Web of Science ®Google Scholar
• Villarreal-Garza C, Vaca-Cartagena BF, Becerril-Gaitan A, Ferrigno AS, Mesa-Chavez F, Platas A, Platas A. Attitudes and factors associated with COVID-19 vaccine hesitancy among patients with breast cancer. JAMA Oncol. 2021;7(8):1242–4. doi:10.1001/jamaoncol.2021.1962.
   PubMed Web of Science ®Google Scholar
• Hong J, Xu X-W, Yang J, Zheng J, Dai S-M, Zhou J, Zhang Q-M, Ruan Y, Ling C-Q. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: a cross-sectional survey. J Integr Med. 2022;20(1):34–44. doi:10.1016/j.joim.2021.10.004.
   PubMedGoogle Scholar
• Chun JY, Kim SI, Park EY, Park S-Y, Koh S-J, Cha Y, Yoo HJ, Joung JY, Yoon HM, Eom BW. et al. Cancer patients’ willingness to take COVID-19 Vaccination: a nationwide multicenter survey in korea. Cancers Basel. 2021;13(15):3883. doi:10.3390/cancers13153883.
   PubMed Web of Science ®Google Scholar
• Overheu O, Lendowski S, Quast DR, Marheinecke CS, Kourti E, Lugnier C, Andreica I, Kiltz U, Pfaender S, Reinacher-Schick A. et al. Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients. J Cancer Res Clin Oncol. 2023;149(5):1985–92. doi:10.1007/s00432-022-04099-7.
   PubMed Web of Science ®Google Scholar
• He Y, Ding Y, Cao B, Huang Y, Wang X. COVID-19 vaccine development from the perspective of cancer patients. Hum Vaccin Immunother. 2021;17(10):3281–7. doi:10.1080/21645515.2021.1943988.
   PubMed Web of Science ®Google Scholar
• Suri TM, Ghosh T, Singhal S, Arunachalam M, Alwani H, Mohan A. COVID-19 vaccine uptake among patients undergoing treatment for lung cancer: a cross-sectional study in India. Lung India. 2023;40(3):294–6. doi:10.4103/lungindia.lungindia_539_22.
   PubMed Web of Science ®Google Scholar
• Liu W, Wu Y, Yang R, Chen R, Huang Y, Zhao X, Xie M, Li Q, Wang Q, Chen J. COVID-19 vaccination status and hesitancy among breast cancer patients after two years of pandemic: a cross-sectional survey. Vaccines. 2022;10(9):1530. doi:10.3390/vaccines10091530.
   Web of Science ®Google Scholar
• Terpos EA-O, Karalis V, Ntanasis-Stathopoulos I, Evangelakou Z, Gavriatopoulou M, Manola MS, Malandrakis P, Gianniou DD, Kastritis E, Trougakos IP, Dimopoulos MA. et al. Comparison of Neutralizing antibody responses at 6 months post vaccination with BNT162b2 and AZD1222 LID. Print. 2022;338(2):2227–9059. doi:10.3390/biomedicines10020338[ doi.
   Google Scholar
• Terpos EA-O, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Sklirou AD, Bagratuni T, Papanagnou ED, Patseas D, Gumeni S, Malandrakis P, et al. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021;96(9):E321–E324. doi:10.1002/ajh.26248.
   PubMed Web of Science ®Google Scholar
• Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer. 2021;159:259–74. doi:10.1016/j.ejca.2021.10.013.
   PubMed Web of Science ®Google Scholar
• Peeters M, Verbruggen L, Teuwen L, Vanhoutte G, Vande Kerckhove S, Peeters B, Raats S, Van der Massen I, De Keersmaecker S, Debie Y. et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open. 2021;6(5):100274. doi:10.1016/j.esmoop.2021.100274.
   PubMed Web of Science ®Google Scholar
• Wankhede D, Grover S, Hofman P. Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: a systematic review and meta-analysis. Vaccine. 2023;41(11):1791–8. doi:10.1016/j.vaccine.2023.01.072.
   PubMed Web of Science ®Google Scholar
• Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2013;2013(8):Cd006484. doi:10.1002/14651858.CD006484.pub3.
   PubMedGoogle Scholar
• Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H. Influenza vaccination in adult patients with solid tumours treated with chemotherapy. Eur J Cancer. 2017;76:134–43. doi:10.1016/j.ejca.2017.02.012.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Poznansky MC. Vaccination of oncology patients: an effective tool and an opportunity not to be missed. Oncologist. 2012;17(1):1–2. doi:10.1634/theoncologist.2011-0383.
   Google Scholar
• Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao Y-Y, Pagala M, Gupta S, Solomon W, Rubin P. et al. Immunogenicity of an inactivated monovalent 2009 influenza a (H1N1) vaccine in patients who have cancer. Oncologist. 2012;17(1):125–34. doi:10.1634/theoncologist.2011-0220.
   PubMed Web of Science ®Google Scholar